![]() There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. This news release contains forward-looking statements. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of integrative mental health clinics and operates a full-service contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics and clinical research sites. To learn more, please visit About Novamind Once approved, patients can immediately use the CareCredit credit card to pay for deductibles, copays and coinsurance, as well as other costs not covered by insurance. "Further to delivering the highest standard of care in a variety of accessible formats, whether it's virtual, in-person, one-on-one or in groups, we're pleased to implement additional flexible patient financing options like CareCredit at our clinics to reduce barriers to care."ĬareCredit enables patients with a quick prequalifying process and applications via mobile device or over the phone, resulting in an instant credit decision. ![]() ![]() "Novamind is committed to ensuring that as many patients as possible can access mental health treatment," said Seneca Anderson, SVP Operations. In a 2021 survey from McKinsey & Company, almost one fourth of respondents reported deferring mental healthcare, with lack of affordable treatment ranking as the top reason why. The Company now accepts Synchrony's CareCredit credit card for treatments including Transcranial Magnetic Stimulation (TMS), ketamine therapy and Spravato therapy.Īffordability of mental healthcare services remains a primary barrier to accessing treatment in the U.S. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, today announced new patient financing options to help patients access critical mental healthcare services at its six clinic locations in Utah. ![]() Or, for lively sector discussion, visit Stockhouse’s new Cannabis Bullboards page.TORONTO, ON / ACCESSWIRE / J/ Novamind Inc. įor more of the latest info on Cannabis, check out the Cannabis Trending News hub. New to investing in Cannabis? Check out Stockhouse tips on How to Invest in Cannabis Stocks and some of our Top Cannabis Stocks. Each Warrant entitles the holder to purchase common shares at an exercise price of CDN$0.50 per common share at any time on or prior to January 26, 2027. ![]() Pursuant to the PP, the company issued 4,750,000 common shares, 7,750,000 common share equivalents (consisting of pre-funded warrants exercisable into common shares) and warrants to purchase up to an aggregate of 12,500,000 common shares, at a purchase price of CDN$0.40 per common share and associated warrant. ( CSE.NM) – a leading mental health company specialized in psychedelic medicine – has announced that it has closed its previously announced private placement (PP) to an institutional investor of its common shares and warrants to purchase common shares for gross proceeds to the company of approximately CDN$5 million. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |